ARCHIVES

Campath Improves PFS In B-Cell CLL In Phase III Trial

This article is from The Cancer Letter archive.

Vol. 30 No. 1 | January 26, 2007

Download PDF Visit The Full Archive

Related Articles

In Brief: San Antonia Cancer Institute Designated Comprehensive; Yeast DNA Described

May 3, 1996

O’Shaughnessy, Burris To Present for Genentech At FDA Hearing At June 28-29

June 10, 2011

NCI, DCT Board Cool Toward AMA, ACOS, VA Role In Clinical Trials

March 3, 1989

In Brief: DCE Board Nixes NIH Intramural Postdoctural Program Magazines Rapped For Cigarette Ads

July 13, 1984

Biomarker Test Outperforms PSA and Gleason Score in Study

July 26, 2013

Kadcyla Extends Median PFS In Open-Label Phase III Trial

October 25, 2013